Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial (Nature Medicine, (2021), 27, 8, (1451-1457), 10.1038/s41591-021-01455-x)

PASSPORT Study Group

Research output: Contribution to journal › Comment/debate

Fingerprint

Dive into the research topics of 'Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial (Nature Medicine, (2021), 27, 8, (1451-1457), 10.1038/s41591-021-01455-x)'. Together they form a unique fingerprint.

Keyphrases

Arts and Humanities

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science